Over the last decade, immune checkpoint blockers, or ICBs, have revolutionized treatment for various advanced cancers, including melanoma, the most aggressive skin cancer that was considered largely incurable not long ago. However, three-fourths of advanced-melanoma patients are resistant to ICBs. Now, researchers reveal a potential target -- using the clinically approved drug ruxolitinib -- to suppress ICB-resistant melanomas.